Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.

Authors

Dean F. Bajorin

Memorial Sloan Kettering Cancer Center, New York, NY

Dean F. Bajorin , Leonard G. Gomella , Padmanee Sharma , Elizabeth R. Plimack , Peter H. O'Donnell , Jean H. Hoffman-Censits , Thomas W. Flaig , David I. Quinn , Dwayne Campogan , Heather Haynes , Candice McCoy , Johnathan Maher , Todd DeVries , Nadeem A. Sheikh , Seth P. Lerner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT01353222

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4541^)

DOI

10.1200/jco.2014.32.15_suppl.4541

Abstract #

4541^

Poster Bd #

109

Abstract Disclosures

FEATURED

Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.

Authors

Dean F. Bajorin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Preliminary safety, product parameters, and immune response assessments from a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy (ACI), in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.

Poster

Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.

Poster

HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.

Poster

NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer.